TrivarX Advances Stabl-Im Brain Imaging Toward Phase 1 Trials with New CEO Appointment

Stabl-Im Nears First-in-Human Trials

TrivarX Limited (ASX:TRI) is advancing its Stabl-Im brain imaging technology toward Phase 1 clinical trials, focusing on early, non-invasive detection of active tumour growth. The platform leverages stable isotope labelling combined with MRI to overcome the limitations of conventional MRI, which typically detects tumours only after structural changes appear. By targeting cellular proliferation rather than anatomy alone, Stabl-Im aims to provide earlier insight into tumour activity and treatment response, potentially reshaping oncology imaging workflows.

During the March quarter, TrivarX refined its clinical study design and engaged early with regulatory bodies in the US and EU to pave a structured pathway for first-in-human studies planned for calendar year 2026. The company is also in advanced discussions with leading Contract Research Organisations (CROs) to support trial execution and site activation, underpinning operational readiness for these pivotal studies. This builds on the company's earlier acquisition and development phases, including manufacturing validation and IP consolidation.

TrivarX continues to explore strategic options for its MEB-001 asset, indicating an openness to alternative commercial pathways beyond the core Stabl-Im program. The company’s approach suggests a focus on capital efficiency and targeted clinical validation as it seeks to unlock broader market opportunities.

Leadership Overhaul to Drive Commercial Focus

Significant management changes during the quarter have positioned TrivarX for its next growth phase. The departure of Chief Medical Officer Dr Archie Defillo marked a shift away from earlier mental health technology development toward a sharper commercial focus on Stabl-Im. The Board has increased its direct involvement in commercialisation, with Non-Executive Directors Dr Tony Keating and Mr Chris Ntoumenopoulos bringing proven expertise from their roles in scaling digital health companies, notably ResApp Health, which was acquired by Pfizer for approximately $180 million in 2022.

Post quarter-end, TrivarX appointed Dr Danielle Meyrick as Chief Executive Officer effective 1 June 2026. Dr Meyrick’s 20-plus years of international experience in clinical medicine, radiopharmaceutical development, and biotechnology commercialisation are expected to materially enhance TrivarX’s clinical and regulatory capabilities. Her background includes leadership roles at Telix Pharmaceuticals (ASX:TLX) and ITM Isotope Technologies Munich, with direct oversight of radiopharmaceutical trials and regulatory submissions across major jurisdictions including the FDA, EMA, and TGA. This appointment aligns with TrivarX’s strategic pivot toward clinical execution and commercialisation of its imaging platform, as detailed in the company's recent CEO appointment details.

Financial Position Supports Development Milestones

TrivarX ended the quarter with a cash balance of $2.91 million, underpinning ongoing clinical and operational activities. The company’s cash burn remains moderate, with $296,000 used in operating activities during the quarter and $168,000 invested in intellectual property development. There were no significant financing activities this quarter, contrasting with previous capital raises, including a $4.2 million placement earlier this year that funded the Stabl-Im acquisition and initial development phases. This financial footing provides TrivarX with an estimated runway of nearly 10 quarters at current operating levels, supporting its planned Phase 1 trial progression and regulatory engagements.

These financials follow TrivarX’s recent successful capital raises and technology acquisitions, which have laid the groundwork for clinical advancement and commercialisation efforts. The company’s strategic focus on capital efficiency and structured clinical development pathways positions it well to navigate the costly and complex early-stage clinical trial landscape, as seen in its prior $4.2M raise and Stabl-Im acquisition.

Next Steps Toward Clinical Validation and Market Entry

Chairman David Trimboli emphasised the foundational progress made in the quarter, highlighting the refinement of study design, regulatory planning, and CRO negotiations as key enablers for the upcoming Phase 1 trials. The company’s leadership changes and governance enhancements are designed to support a more commercially oriented development phase, reflecting a clear strategic intent to translate Stabl-Im’s scientific promise into clinical and market value.

Looking ahead, TrivarX’s priorities include finalising trial protocols, securing partnerships to facilitate trial execution, and building a robust evidence base to demonstrate Stabl-Im’s clinical utility. The company’s ability to execute these milestones will be critical in validating its technology’s potential to disrupt brain tumour imaging and expand its footprint in oncology diagnostics.